Aptevo Therapeutics Inc. — Form 8-K
Filed October 23, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
Aptevo Therapeutics amended its Rights Agreement (poison pill) on October 23, 2026. The amendment extends the expiration date from October 29, 2026 to October 23, 2027 (one-year extension). The Purchase Price for exercising rights was reduced from $70 per one-thousandth of a Preferred Share to $14.56 per one-thousandth of a Preferred Share—a 79% reduction. No other material terms changed; Broadridge Corporate Issuer Solutions remains rights agent.
Why this rating
For a $9.8M market-cap company, poison pill amendments are material governance acts. The 79% cut to exercise price materially weakens anti-takeover defenses, lowering the cost for an acquirer to trigger dilution. Combined with one-year extension, this signals potential distress or shareholder pressure. Significant for small-cap governance and control risk.
Price action (we called it negative)
at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.